Novo to cut US list prices for Wegovy and Ozempic next year.

Novo Nordisk will set a $675 monthly US list price for its semaglutide medicines, cutting some list prices by up to 50%, and said the change takes effect on Jan. 1 to give payers time to prepare.

Novo Nordisk said it will lower the published US wholesale acquisition cost for its semaglutide medicines, including Wegovy and Ozempic, and set a uniform monthly list price of $675. The company framed the move as a way to be more competitive in the obesity market after losing market share to a rival. Novo said the list price change will take effect on Jan. 1 and that payers were notified in advance. Company officials noted the cuts apply to published list prices and do not directly change the complex rebate arrangements in the US market. Key details: - Novo set a $675 monthly list price across its semaglutide family, representing reductions of as much as about 50% for some products. - The price change applies to the wholesale acquisition cost (published list price) and does not automatically change existing self-pay prices or rebate arrangements. - Novo said the move may reduce out-of-pocket costs for patients with high-deductible plans or co-insurance tied to list prices. - The company noted the list price cut is separate from a Medicare discount negotiated last year and said the change alone will not affect net sales in isolation. - The announcement compared current competitor list pricing, noting Zepbound's published list price was reported at about $1,086.37 and that commercial insurance copays for these drugs can be as low as $25 a month. Summary: The announced list-price reductions set a uniform published monthly price and are intended to make Novo's semaglutide medicines more competitive in the US obesity market. Novo said the change starts on Jan. 1 and that payers were given time to prepare; how much it will alter net spending or patient experiences will depend on insurance plan designs and existing rebate arrangements.